The solutions used in our studies were the lowestconcentrations of both sclerosants commonly used for sclerotherapy treatment, i.e. 0.25% Aethoxysklerol and 0.2% Fibro-vein. We chose those concentrated solu- tions because of the unavailability of Fibro-vein at higher concentrations on the official drug market in Italy at the moment of writing of this manuscript.